
  <style>
  .gh-table table { 
    border-collapse: collapse; 
    width: 100%;
    border: 1px solid #444;
    font-size: 12px;
  }
  .gh-table th, .gh-table td { 
    border: 1px solid #444; 
    padding: 4px 6px; 
    vertical-align: top;
    font-weight: 400 !important;   /* regular font */
  }
  .gh-table th { 
    .gh-table th { background: #f5f5f5; text-align: left; }
  }
  .gh-table th { font-weight: 700 !important; }
    @media print {
      .gh-table { font-size: 10px; }
    }
  </style>
  <div class='gh-table'><table><thead><tr><th>record_id</th><th>visit</th><th>Molecola (1)</th><th>Molecola (2)</th><th>description</th></tr></thead><tbody><tr><td>H15</td><td>1</td><td>Acebutolol</td><td>Acetylsalicylic acid</td><td>Acetylsalicylic acid may decrease the antihypertensive activities of Acebutolol.</td></tr><tr><td>H15</td><td>1</td><td>Acebutolol</td><td>Cholecalciferol</td><td>The metabolism of Acebutolol can be decreased when combined with
Cholecalciferol.</td></tr><tr><td>H15</td><td>1</td><td>Acebutolol</td><td>Cobicistat</td><td>The metabolism of Acebutolol can be decreased when combined with Cobicistat.</td></tr><tr><td>H15</td><td>1</td><td>Acebutolol</td><td>Furosemide</td><td>Furosemide may increase the hypotensive activities of Acebutolol.</td></tr><tr><td>H15</td><td>1</td><td>Atorvastatin</td><td>Cobicistat</td><td>The serum concentration of Atorvastatin can be increased when it is combined
with Cobicistat.</td></tr><tr><td>H15</td><td>1</td><td>Darunavir</td><td>Acebutolol</td><td>The metabolism of Acebutolol can be decreased when combined with Darunavir.</td></tr><tr><td>H15</td><td>1</td><td>Darunavir</td><td>Atorvastatin</td><td>The metabolism of Atorvastatin can be decreased when combined with Darunavir.</td></tr><tr><td>H15</td><td>1</td><td>Darunavir</td><td>Cholecalciferol</td><td>The metabolism of Cholecalciferol can be decreased when combined with Darunavir.</td></tr><tr><td>H15</td><td>1</td><td>Darunavir</td><td>Dolutegravir</td><td>The serum concentration of Dolutegravir can be increased when it is combined
with Darunavir.</td></tr><tr><td>H15</td><td>1</td><td>Dolutegravir</td><td>Cobicistat</td><td>Cobicistat may decrease the excretion rate of Dolutegravir which could result in
a higher serum level.</td></tr><tr><td>H15</td><td>1</td><td>Furosemide</td><td>Acetylsalicylic acid</td><td>The risk or severity of increased serum creatinine can be increased when
Acetylsalicylic acid is combined with Furosemide.</td></tr><tr><td>H15</td><td>1</td><td>Zofenopril</td><td>Acebutolol</td><td>Acebutolol may increase the hypotensive activities of Zofenopril.</td></tr><tr><td>H15</td><td>1</td><td>Zofenopril</td><td>Acetylsalicylic acid</td><td>The therapeutic efficacy of Zofenopril can be decreased when used in combination
with Acetylsalicylic acid.</td></tr><tr><td>H15</td><td>1</td><td>Zofenopril</td><td>Furosemide</td><td>The risk or severity of renal failure and hypotension can be increased when
Furosemide is combined with Zofenopril.</td></tr></tbody></table></div>
